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ABSTRACT
We report on the clinical status of 5 patients
with Parkinson’s disease (PD) 3 years after au-
tologous adrenal medullary (AM)-to-caudate
nucleus (CN) implantation, and of 2 PD pa-
tients, 2 years after fetal ventral mesencephalon
(VM)- and fetal adrenal (A)-to-CN homotrans-
plantation. Current clinical evaluation of4 ofthe
AM grafted patients revealed sustained bilateral
amelioration of their PD signs, most notably of
rigidity, postural imbalance and gait distur-
bances, resulting in a substantial improvement
in their quality of life. The disease-related dysto-
nia ofone ofthem disappeared only 2 years after
surgery. The levodopa requirements of2 ofthese
patients and the antichoHnergic therapy of an-
other have been reduced. In agreement with the
satisfactory clinical evaluation of these 4 pa-
tients, their neuropsychological and electro-
physiological improvements, initially registered
3 months after surgery, have been maintained
for 3 years. After 1 year of significant recovery,
the 5th patient of this group has almost returned
to her preoperative state.
The 2 homotransplanted patients also showed
sustained bilateral improvement of their PD
signs. Two years after surgery, the most im-
proved signs of the fetal VM case were rigidity,
bradykinesia, postural imbalance, gait distur-
bances and facial expression. The fetal A case
has only shown amdioration of rigidity and
bradykinesia. Neither of them has shown
significant neuropsychological changes. Their
current levodopa requirements are less than
before surgery.
The improvements shown here by PD patients
after brain tissue grafts go beyond those
obtained using any other therapeutic approach,
when levodopa fails. Although more studies and
the development of these procedures are
obviously required, these initial human trials
appear to be resisting the test oftime.
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INTRODUCTION PATIENTSAND METHODS
Parkinson’s disease (PD) is a chronic,
progressive neurological disorder of unknown
cause, mainly duc to the degeneration of
nigrostriatal dopamincrgic neurons, that leads to
scvcrc disturbances of motor function. To date,
there have bccn no reports of spontaneous
remission of the disease. For a few years, the
deficient ncurotransmission can bc corrcctcd
and the symptoms and signs ameliorated with
exogenous lcvodopa/1/. In time, however, with
the progression of the disease, patients also
become tolerant to the drug/18/, and/or develop
adverse side effects, trapping the patient in an
untrcatablc and most disabling situation.
With the aim of providing a therapeutic
alternative for these patients, wc turned to the
use of dopaminc (DA)-rich brain grafts [adult
adrenal medullary (AM), fetal ventral
mcscnccphalon (VM) and fetal adrenal (A)
tissues/ which, implanted in the striatum of
animal models of the disease, improved their
motor disturbances/2/. In 1987 wc reported/8/
on the short term beneficial effects of autologous
DA-rich AM brain transplants to the caudatc
nucleus (CN) of two patients suffering from PD.
In 1988, wc presented the initial beneficial
effects of fetal VM and fetal A implants to the
first 2 homotransplantcd parkinsonians /17/.
Because of the sustained amelioration of their
PD signs, wc gradually extended our brain
transplantation program, and have now auto-
transplanted a total of 67 patients (60 using our
cavitation procedure/8,10,16/, 5 with a multiple
site implantation technique/7/.and 2 with AM-
intercostal peripheral ncvc co-grafts), and a
total of 7 parkinsonians have received human
fetal tissue.
The therapeutic value of these ncurosurgical
procedures in treating PD rests on the fact that
they should produce long lasting beneficial
effects. It has thus bccn our concern to monitor
carefully our patients over time/9,11,13-16/, in
order to establish the effectiveness of these
surgical procedures. Hcrc wc present the follow-
up of the 5 autotransplantcd parldnsonians who
have reached 3 years after surgery, and the 2
year follow-up of the first 2 patients with fetal
homotransplants.
Clinical data
The 5 autotransplanted patients included 3
males (JMC, farmer, with a grade school
education; FPT, subway employee, with a grade
school education; NAG, civil engineer), and 2
females (MSP, housewife, with a grade school
education; MAO, assistant accountant), all of
them unable to work. Their ages at surgery were
35, 47 and 33, and 51 and 59 years, respectively.
The durations of their illness were 5, 8 and 10,
and 5 and 5 years, respectively. Three of the
patients were under chronic levodopa therapy.
FPT was receiving 1,000 mg/day, NAG 500
mg/day and MAO 1,750 mg/day. The other 2
could not tolerate levodopa. One ofthem (JMC)
did not tolerate any medication, and the other
(MSP) was being treated with an anticholinergic
drug (biperiden) at a dose of 8 mg/day. Patients
on levodopa therapy presented "on-off’
phenomena, and dyskinesia during their "on"
periods. MSP showed disease-related dystonia.
The patient who underwent fetal VM brain
homotransplantation was a 50-year-old sales-
man, with a grade school education (MTM), who
had had PD for 9 years, was receiving 1,000
mg/day of levodopa, and presented drug-induced
dystonia and dyskinesia. The patient who
received the fetal A graft was a 35-year-old
housewife, with secretarial training (LBC), with a
5 year evolution of PD, and who was on 750
rag/day of levodopa.
The pre- and postoperative severity of the
disease was measured on the Unified
Parkinsonism Rating Scale (UPRS) /21/, the
Hoehn and Yahr/5/, the Schwab and England
/20/and our performance scales/8,16/. Patients
were also subjected to pre- and postoperative
neuropsyehologieal /19/ and eleetrophysiologieal
evaluations.
Brain and adrenal gland computed tomo-
graphy, brain magnetic resonance imagings
(MRI), and brain scintigraphy /4/ were obtained
at various times throughout the study. Fig. 1
shows the brain MRI ofMTM (the first VM-CN
fetal homotransplanted patient) 30 months
postsurgery. Further details are given in the
Figure legend.
Biochemical analyses of lumbar and
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ventricular CSF /3/ were discontinued 1 year
postsurgery for ethical considerations.
Brain MRI of MTM (first VM-to-CN fetal
homotransplanted patient) 30 months
postsurgery. Ventricular asymmetry is due to
hypotrophy of the right CN. Paraventricular
images reveal heterogeneous hyper-
intensities of the right CN, possibly due to
gliosis and/or the graft. Slight cortico-
subcortical atrophy is evident. Postsurgical
right frontal lobe gliosis and craniotomy are
visible. (Courtesy of the Department of
Magnetic Resonance Imaging, Hospital
Angeles del Pedregal, Mexico City).
Surgery
The brain transplantation method we
designed to implant both freshly excised
autologous AM fragments or human fetal tissue
has been described in detail elsewhere/10,12,16/.
Human fetalVM was dissected with a hands-free
technique in order to ensure the intactness of the
tissue/6/.
RESULTS
AM autotransplants
Table 1 shows the UPRS scores of the 5 auto-
transplanted parkinsonians in their preoperative
and postoperative conditions 1 and 3 years after
surgery. One (JMC) had severe PD and 4 were
moderate to severe cases. Three years after
surgery, 4 of them have maintained the level of
recovery seen at one year postsurgery, that is,
have maintained a change on the UPRS of more
than 30 points. Improvements were observed in
the length and quality of the "on" periods, as well
as in the reduced frequency of motor fluctua-
tions. In fact, the 2 patients now on a reduced or
suppressed levodopa therapy have stopped fluc-
tuating. Patients’ recovery has been bilateral and
symmetric. The most improved signs have been
rigidity, postural imbalance and gait distur-
bances.
Three of the AM transplanted patients im-
proved progressively until they reached a steady
state approximately 6 to 10 months post-
transplant, which has remained stable now for 3
years. During this time, patients showed oscilla-
tions in the intensity of their PD signs, usually
related to their depressive state, stress, and/or
levodopa dosage adjustments. However, none of
these patients has shown a sustained regression
of symptoms, In one patient (MSP), the disease-
related dystonia, which was manifest at her one
year evaluation, notably disappeared 2 years af-
ter surgery. MAO, who showed a moderate re-
sponse to surgery one year after brain grafting,
has become worse over t/me, although in "on",
she has not deteriorated to her preoperative
state. AM patients’ evaluations on the Hoehn
and Yahr, Schwab and England, and on our per-
formance scales were congruent with these re-
sults. Preoperatively all patients were occupa-
tionally impaired. After surgery, 3.of them (JMC,
NAG, MSP) have been able to return to their
original occupations, and one of them (FPT) is
now a merchant. MAO has remained impaired.
The current postoperative levodopa therapy
of the autotransplanted patients is indicated in
Table 2. Of the 3 autotransplanted patients who
were taking levodopa before surgery, the current
postoperative dose of one of them (NAG) has
been significantly reduced, and that of another
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TABLE 1
Pre- and postoperativeUPRS scores ofautoadrenal medullary brain transplanted parkinsonians
Patient Preoperative
ONa OFFb
CURRENT
Postoperative Preoperative"’ iostoperative CLINICAL
I year 3 years 1 year 3 years STATUS
JMC
FPT 56
NAG 58
MSP
MAO 80
121 82 80 good
75 40 43 good
8 6 86 15 18 good
80 31 26 good
60 72 85 55 86 poor
apeak response to medication or best moment.
bWorst spontaneous or induced moment.
(FPT) suppressed. For MAO, levodopa has in-
creased in the last 2 years, due to progressive
deterioration. One (JMC) of the 2 patients
intolerant to this medication before surgery, and
who did well without levodopa for 15 months
postsurgery, currently requires and is responding
well to.small doses of the drug (375 mg/day),
while the other (MSP) is doing well on a lower
dose of antieholinergic medication (biperiden, 3
rag/day), without the use oflevodopa.
Pre- and postoperative neuropsyehological
and eleetrophysiological (P300) profiles of MSP
are shown in Figs. 2 and 3, respectively. In her
preoperative neuropsyehological evaluation,
MSP showed frontal lobe-type deficits, with al-
terations in behavioral programming, leading to
difficulties in the organization of motor se-
quences and alternating programs. Visuospatial
and visuoperceptual tasks were also affected,
showing loss of figure-ground perspective and
fragmentation. Immediate memory was dimin-
ished, and there were marked difficulties in de-
layed memory. There was formal perseveration
of reading and writing, although motor problems
affected the quality of the written product. She
could perform basic arithmetical operations, but
had difficulty counting backwards from 100 in
TABLE 2
Pro- and postoperative levodopa therapy ofautoadrenal
medullary brain transplanted parkinsonians
mg/day
Patient Preoperative Postoperative
1 year 3 years
JMC 0 0 375
FPT 1000 0 0
NAG 500 250 250
MSPa 0 0 0
MAO 1750 375 1000
Has been on an anticholinergic therapy Coiperiden):
preoperative dose: 8 mg/day; postoperative dose of
years, 3 mg/day.
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Fig. 2: Neuropsychological profiles of MSP before and 3 and 36 months after AM-to-CN autotransplantation.
Higher scores reflect a greater number of errors than average and lower scores the opposite. M: months.
7’s. MSP’s postoperative evaluation, carried out
3 months after surgery, revealed an amelioration
of frontal-lobe symptoms, and of visuospatial
deficits, as well as the improved quality of her
writing due to an important reduction in tremor.
These improvements remained unchanged after
36 months. Of the 5 AM autotransplanted pa-
tients, 3 of them showed specific cognitive
deficits in their preoperative neuropsyehologieal
evaluations. The postoperative evaluations of 2
of these patients revealed an amelioration of
:heir frontal-lobe type symptoms and visuospa-
tial deficits that has been maintained for 36
months. In the ease of MAO, only minor neu-
ropsyehologieal improvements were observed
one year after surgery, and at her 36-month
evaluation her neuropsyehologieal profile proved
to be very similar to her preoperative state. FPT,
who preoperatively showed a depressive symp-
tomatology, has suffered recurrent depressive
episodes after surgery that have been controlled
pharmacologically.
Electrophysiologieal data, obtained from long
latency auditory evoked potentials, have
revealed a significant change in the amplitude of
the P300 component and a shortening of the
latency of the N100 component that have been
sustained in 3 patients for 36 months post-
surgery.
Fetal homotransplants
The postoperative UPRS courses in "on" and
"off’ of the 2 homotransplanted parkinsonians
are shown in Fig. 4, together with the corre-
sponding levodopa requirements. MTM with the
VM homograft, 5 months after surgery, had sig-
nifican amelioration of rigidity, bradykinesia,
postural imbalance, gait disturbances and facial
expression, but tremor was a remaining sign. At
his 2 year evaluation, tremor has further de-
creased and, in general, his current clinical status
is very good. Today, he leads a normal life, and
has gone back to work.
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Fig. 3: Electrophysiological profiles of MSP before and 3, 9 and 36 months after AM-to-CN autotransplantation. M:
months.
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Fig. 4: Two year postoperative UPRS courses in "on"
and "off’ of the first 2 parkinsonians
homotransplanted with fetal VM or fetal A.
LBC, the fetal A transplanted patient, has.
shown significant amelioration of only rigidity
and bradykinesia, without important changes in
the other signs. Though her current clinical sta-
tus is moderate, she is now able to perform
household tasks. Her current levodopa require-
ments are much closer to her preoperative level
of medication, compared with MTM, whose cur-
rent levodopa intake is only half that of his pre-
operative dose. Both patients have been main-
tained on 1 mg/kg PO eyclosporin A, with serum
levels ranging between 150-200 ng/ml (Sandoz,
R/A).
CONCLUDING REMARKS
From these data, we may conclude that 3
years after autoadrenal transplantation, and 2
years after fetal VM or A homotransplantation,
to varying degrees, and regardless of the
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mechanisms of action involved, these brain
transplantations are effective procedures to
ameliorate PD signs to an extent not achieved
by any other means. Currently, efforts are being 7.
devoted to establish the best candidates for
surgery and the best donor tissue, as well as the
best implantation technique.
We strongly believe that, with the current
state of knowledge regarding brain transplanta-
tions, we cannot disregard the usefulness of any
type of graft for the treatment of neurological 8.
diseases. Though at this time fetal tissue seems
to be the most useful graft, autotransplants,
which do not require immunosuppression, as
well as genetically modified cells, will in time 9.
assume their place as implantation alternatives
for each individual patient.
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